

Mangalam Drugs and Organics Limited

Regd. Office : Rupam Building, 3rd Floor, 239 P. D'Mello Road, Near G. P. O. Mumbai - 400 001.
☎ 91-22-62616200 / 6300 / 8787 ☎ 91-22-62619090 • CIN : L24230MH1972PLC116413



REF: MDOL/CS-SE/2025- 26/017

August 07, 2025

To,
Listing Department
BSE Ltd
1st Floor, New Trade Wing,
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai - 400 001.
Scrip Code: 532637

Listing Department
National Stock Exchange of India Limited
"Exchange Plaza", 5th Floor,
Plot No. C-1, Block G,
Bandra - Kurla Complex,
Bandra(E), Mumbai - 400 051
Symbol: MANGALAM

Sub: Outcome of the Board Meeting held on Thursday, August 07, 2025

Ref: Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI LODR Regulations) read with SEBI Circular CIR / CFD / CMD / 4 / 2015 dated September 09, 2015

Dear Sir / Madam,

With respect to the captioned subject and mentioned reference, we are pleased to inform that the Board of Directors of the Company, in their meeting held today i.e., Thursday, August 7, 2025 has *inter-alia* transacted, considered and approved the following business:

- The Un-Audited Financial Results (Standalone and Consolidated) along with the Limited Review Report of the Company for the quarter ended June 30, 2025 pursuant to Regulation 33 of the SEBI LODR Regulations. (A copy of the said results, notes thereto and Limited Review Report is annexed hereto and marked as Annexure I.)

Pursuant to Regulation 33(3)(d) of the Listing Regulations, we hereby declare that in respect of the Un-Audited Financial Results (Standalone and Consolidated) for the quarter ended June 30, 2025, the statutory Auditors have not expressed any modified opinion(s) in their Audit Reports.

The Board meeting commenced at 4:00 P.M. and concluded at 7:30 P.M.

We request you to take the same on your records.

Thanking You,

Yours faithfully,
For **Mangalam Drugs & Organics Limited**

Govardhan M. Dhoot
Chairman & Managing Director
DIN: 01240086

MANGALAM DRUGS AND ORGANICS LIMITED


CIN - L24230MH1972PLC116413

Rupam Building, 3rd Floor, 239, P.D'Mello Road, Near G.P.O, Mumbai - 400 001.



Statement of Standalone Unaudited Financial Results for the Quarter Ended June 30, 2025

Sr.No	Particulars	Quarter Ended			(Rs. In Lakhs)
		30.06.25	31.03.2025	30.06.2024	Year Ended
		Unaudited	Audited	Unaudited	31.03.2025
					Audited
1	Income from Operations				
	(a) Net Sales and Services from Operations	5,720.87	7,277.73	7,649.41	31,757.60
	(b) Other Operating Income	14.00	26.13	4.21	65.42
	Total Income from Operations (net) (a+b)	5,734.87	7,303.86	7,653.62	31,823.02
2	Expenses				
	(a) Cost of Materials Consumed	2,333.37	4,176.39	4,053.44	17,056.16
	(b) Purchase of Stock in trade	-	618.71	607.28	1832.79
	(c) Changes in Inventories of, Finished Goods, Work In Progress and Stock-in-trade	1,624.53	(1,258.61)	(619.80)	(2,152.20)
	(d) Employee Benefit Expenses	931.25	1,050.34	956.85	4,058.71
	(e) Depreciation and amortization expenses	438.09	460.93	387.34	1,637.78
	(f) Other Expenses (Refer Note No. 6)	1,296.02	1,701.54	1,835.72	7,447.33
	Total Expenses (a to f)	6,623.26	6,749.30	7,220.83	29,880.57
3	Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)	(888.39)	554.56	432.79	1,942.45
4	Other Income	0.04	21.05	2.02	49.75
5	Profit / (Loss) from ordinary activities before finance costs and exceptional items (3+4)	(888.35)	575.61	434.81	1,992.20
6	Finance costs (net)	404.45	403.01	376.34	1,493.26
7	Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5-6)	(1,292.80)	172.60	58.47	498.94
8	Exceptional items	0.00	0.00	0.00	0.00
9	Profit/(Loss) from ordinary activities before tax (7-8)	(1,292.80)	172.60	58.47	498.94
10	Tax Expenses				
	(a) Current Tax	0.00	7.27	-	8.27
	(b) Deferred Tax	80.00	150.24	(210.00)	(201.76)
	Total Tax Expenses (a+b+c+d)	80.00	157.51	(210.00)	(193.49)
11	Net Profit(+)/Loss(-) from ordinary activities after tax (9-10)	(1,372.80)	15.09	268.47	692.43
12	Extraordinary Items	0.00	0.00	0.00	0.00
13	Net Profit(+)/Loss (-) for the period(11-12)	(1,372.80)	15.09	268.47	692.43
14	Share of Profit / (Loss) of associates	-	-	-	-
15	Minority Interest	-	-	-	-
16	Net Profit / (Loss) after taxes, minority interest and share of Profit / -(Loss) of associates (13-14-15)	(1,372.80)	15.09	268.47	692.43
17	Other Comprehensive income not reclassified into Profit and loss account (Net of Taxes)	(11.42)	(19.59)	(13.99)	(61.57)
18	Total Comprehensive Income (16+17)	(1,384.22)	(4.50)	254.48	630.86
18	Paid-up Equity Share Capital (Face value of Rs 10/- per share)	1,582.82	1,582.82	1,582.82	1,582.82
19	Reserve excluding Revaluation Reverses as per balance sheet of previous accounting year				13,282.79
20	Earnings Per Share (EPS) (of Rs 10/-each not annualised):				
	(a) Basic	(8.67)	0.10	1.70	4.37
	(b) Diluted	(8.67)	0.10	1.70	4.37



MANGALAM DRUGS AND ORGANICS LIMITED

CIN - L24230MH1972PLC116413

Rupam Building, 3rd Floor, 239, P.D'Mello Road, Near G.P.O, Mumbai - 400 001.



Notes :

- 1 The above financial results have been prepared in accordance with Indian Accounting Standard (Ind AS) notified under section 133 of the companies Act, 2013, read together with Companies (Indian Accounting Standard) Rules, 2015 and relevant amendment rules thereafter.
- 2 The above unaudited standalone financial results of the Company for the Quarter ended have been reviewed by the Audit Committee and thereafter, approved and taken on record by the Board of Directors of the Company (Mangalam Drugs and Organics Limited) at their meeting held on August 7, 2025.
- 3 The Company's business activity falls within a single reportable Business Segment Viz. "Manufacturing of Bulk Drugs".
- 4 The figures for the quarter ended March 31, 2025 are the balancing figures between the audited figures in respect of full financial year upto March 31, 2025 and the unaudited published year-to-date figures upto December 31, 2024 being the date of the end of the third quarter of the financial year respectively whichever subjected to limited review.
- 5 The Board of Directors of the Company at its meeting held on March 15, 2024 and which has been further modified on June 18, 2024 considered and approved the scheme of Merger by Absorption of Mangalam Laboratories Private Limited ("First Transferor Company") and Shri JB Pharma Private Limited ("Second Transferor Company") with Mangalam Drugs and Organics Limited ("Transferee Company") and their respective shareholders under Sections 230 to 232 and other applicable provisions of the Companies Act, 2013. The Scheme is subject to approval of Hon'ble National Company Law Tribunal. Tribunal has convened meeting for the creditors and shareholders has been scheduled for 12th August 2025.


6 Other Expenses

Sr.No	Particulars	Rs in Lakhs			
		Quarter Ended		Year Ended	
		30.06.25	31.03.2025	30.06.2024	31.03.2025
		Unaudited	Audited	Unaudited	Audited
1	Power and Fuel Expenses	446.30	662.75	610.83	2,788.18
2	Pollution Control Expenses	168.30	269.30	223.03	901.14


7 The figures for the previous periods have been regrouped wherever necessary to confirm to the current periods under presentation.

On behalf of Board of Directors
For Mangalam Drugs and Organics Limited

(Signature)
Shri Govardhan M. Dhoot
Chairman and Managing Director
DIN:01240086



Place: Mumbai
Date: 7th August, 2025





Limited Review Report on Unaudited Standalone Financial Results of Mangalam Drugs and Organics Limited for the Quarter ended on 30th June, 2025 and year to date results for the period from 1st April, 2025 to 30th June, 2025 pursuant to Regulation 33 and Regulation 52(4) read with Regulation 63 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, as prescribed in Securities and Exchange Board of India operational circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10th August 2021 as amended.

The Board of Directors,
Mangalam Drugs and Organics Limited,


1. We have reviewed the accompanying statement of unaudited financial results of **Mangalam Drugs and Organics Limited** (the "Company") for the quarter ended on 30th June 2025 (the "Statement") attached herewith, being submitted by the Company, pursuant to the requirements of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, and other accounting principles generally accepted in India and in compliance with Regulation 33 and Regulation 52(4) read with regulation 63 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended as prescribed in Securities and Exchange Board of India operational circular SEBI/HO/DDHS/P/CIR/2021/613 dated August 10, 2021. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



4. Conclusion:

Based on our review conducted as above nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For V.S. SOMANI & Co.,
Chartered Accountants
Firm Registration No. 117589W




CA Vidyadhar Somani
Proprietor
Membership No.102664
UDIN No. 25102664BMITHL9018

Place: Mumbai
Date: 7th August, 2025

MANGALAM DRUGS AND ORGANICS LIMITED
CIN - L24230MH1972PLC116413

Rupam Building, 3rd Floor, 239, P.D'Mello Road, Near G.P.O, Mumbai - 400 001.

Sr.No	Particulars	(Rs. In Lakhs)			
		Quarter Ended			Year Ended
		30.06.2025	31.03.2025	30.06.2024	31.03.2025
		Unaudited	Audited	Unaudited	Audited
A) Part-1 Consolidated Statement of Un-Audited Financial Results for the Quarter Ended June 30, 2025					
1	Income from Operations				
	(a) Net Sales and Services from Operations	5,720.87	7,277.73	7,649.41	31,757.60
	(b) Other Operating Income	14.00	26.13	4.21	65.42
	Total Income from Operations (net) (a+b)	5,734.87	7,303.86	7,653.62	31,823.02
2	Expenses				
	(a) Cost of Materials Consumed	2,333.37	4,176.39	4,053.44	17,056.16
	(b) Purchase of Stock in trade	-	618.71	607.28	1,832.79
	(c) Changes in Inventories of, Finished Goods, Work In Progress and Stock-in-trade	1,624.53	(1,258.61)	(619.80)	(2,152.20)
	(d) Employee Benefit Expenses	938.10	1,050.34	956.85	4,058.71
	(e) Depreciation and amortization expenses	447.57	470.42	387.80	1,660.70
	(f) Other Expenses (Refer Note No. 6)	1,286.71	1,701.19	1,835.27	7,445.28
	Total Expenses (a to f)	6,630.28	6,758.44	7,220.83	29,901.44
3	Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)	(895.41)	545.42	432.78	1,921.58
4	Other Income	0.04	21.04	2.02	50.26
5	Profit / (Loss) from ordinary activities before finance costs and exceptional items (3+4)	(895.37)	566.46	434.80	1,971.84
6	Finance costs (net)	404.46	403.01	376.34	1,493.26
7	Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5-6)	(1,299.83)	163.45	58.46	478.58
8	Exceptional items	-	-	-	-
9	Profit/(Loss) from ordinary activities before tax (7-8)	(1,299.83)	163.45	58.46	478.58
10	Tax Expenses				
	Current Tax	-	7.27	-	8.27
	Deferred Tax	80.00	150.24	(210.00)	(201.76)
	Total Tax Expenses (a+b)	80.00	157.51	(210.00)	(193.49)
11	Net Profit(+)/Loss(-) from ordinary activities after tax (9-10)	(1,379.83)	5.94	268.46	672.07
12	Extraordinary Items	-	-	-	-
13	Net Profit(+)/Loss (-) for the period(11-12)	(1,379.83)	5.94	268.46	672.07
14	Share of Profit / (Loss) of associates	-	-	-	-
15	Minority Interest	-	-	-	-
16	Net Profit / (Loss) after taxes, minority interest and share of Profit / -(Loss) of associates (13-14-15)	(1,379.83)	5.94	268.46	672.07
17	Other Comprehensive income not reclassified into Profit and loss account (Net of Taxes)	(11.42)	(19.59)	(13.99)	646.55
	Total Comprehensive Income (16+17)	(1,391.25)	(13.65)	254.47	1,318.62
18	Paid-up Equity Share Capital (Face value of Rs 10/- per share)	1,582.82	1,582.82	1,582.82	1,582.82
19	Reserve excluding Revaluation Reverses as per balance sheet of previous accounting year	-	-	-	12,606.96
20	Earnings Per Share (EPS) (of Rs 10/-each not annualised):				
	(a) Basic	(8.72)	0.04	1.70	4.25
	(b) Diluted	(8.72)	0.04	1.70	4.25





MANGALAM DRUGS AND ORGANICS LIMITED
CIN - L24230MH1972PLC116413



Rupam Building, 3rd Floor, 239, P.D'Mello Road, Near G.P.O, Mumbai - 400 001.

Notes :

1	The above financial results have been prepared in accordance with Indian Accounting Standard (Ind AS) notified under section 133 of the companies Act, 2013, read together with Companies (Indian Accounting Standard) Rules, 2015 and relevant amendment rules thereafter.				
2	The above unaudited Consolidated financial results of the Company for the Quarter ended have been reviewed by the Audit Committee and thereafter, approved and taken on record by the Board of Directors of the Company (Mangalam Drugs and Organics Limited) at their meeting held on August 7, 2025.				
3	The Company's business activity falls within a single reportable Business Segment Viz. "Manufacturing of Bulk Drugs".				
4	The figures for the quarter ended March 31, 2025 are the balancing figures between the audited figures in respect of full financial year upto March 31, 2025 and the unaudited published year-to-date figures upto December 31, 2024 being the date of the end of the third quarter of the financial year respectively whichever subjected to limited review.				
5	Consolidated results includes results of Mangalam Laboratories Private Limited & subsidiary for the purpose of Consolidated results. The wholly owned subsidiary is not a material subsidiary of the Company.				
6	Other Expenses				
		Rs in Lakhs			
		Quarter Ended		Year Ended	
Sr.No .	Particulars	30.06.25	31.03.2025	30.06.2024	31.03.2025
		Unaudited	Audited	Unaudited	Audited
1	Power and Fuel Expenses	446.44	662.83	611.03	2,788.76
2	Pollution Control Expenses	168.30	269.30	223.03	901.14
7	The Board of Directors of the Company at its meeting held on March 15, 2024 and which has been further modified on June 18, 2024 considered and approved the scheme of Merger by Absorption of Mangalam Laboratories Private Limited ("First Transferor Company") and Shri JB Pharma Private Limited ("Second Transferor Company") with Mangalam Drugs and Organics Limited ("Transferee Company") and their respective shareholders under Sections 230 to 232 and other applicable provisions of the Companies Act, 2013. The Scheme is subject to approval of Hon'ble National Company Law Tribunal. Tribunal has convened meeting for the creditors and shareholders has been scheduled for 12th August 2025.				
8	The figures for the previous periods have been regrouped wherever necessary to confirm to the current periods under presentation.				
	Place: Mumbai Date: August 7, 2025	On behalf of Board of Directors For Mangalam Drugs and Organics Limited  Shri Govardhan M. Dhoot Chairman and Managing Director DIN:01240086			





Limited Review Report on Unaudited Consolidated Financial Results of Mangalam Drugs and Organics Limited for the Quarter ended on 30th June, 2025 and year to date results for the period from 1st April, 2025 to 30th June, 2025 pursuant to Regulation 33 and Regulation 52(4) read with Regulation 63 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, as prescribed in Securities and Exchange Board of India operational circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10th August 2021 as amended.

To the Board of Directors,
Mangalam Drugs and Organics Limited

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of **Mangalam Drugs and Organics Limited** (hereinafter referred to as "the Parent"), its subsidiary (the Parent and its subsidiary together referred to as "the Group") and its share of the net profit after tax and total comprehensive income of its subsidiary for the quarter ended on 30th June 2025 ("the Statement"), being submitted by the Parent pursuant to the requirements of Regulation 33 and Regulation 52(4) read with Regulation 63 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"), as prescribed in Securities and Exchange Board of India operational circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10th August 2021.
2. This Statement, which is the responsibility of the Parent's management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 and Regulation 52(4) read with Regulation 63 of the Listing Regulations, as prescribed in Securities and Exchange Board of India operational circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10th August 2021. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. We also performed procedures in accordance with the circular



issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The statement includes the results of the Mangalam Laboratories Private Limited a subsidiary, which is not a material subsidiary.
5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 and Regulation 52(4) read with Regulation 63 of the Listing Regulations, as prescribed in Securities and Exchange Board of India operational circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10th August 2021, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. We did not review the interim financial results of a subsidiary included in the Statement, whose interim financial results reflects total revenues (before consolidation adjustments) of Rs. 10.09 Lakhs total net loss after tax and total comprehensive income (before consolidation adjustments) of Rs. 7.03 Lakhs for the quarter ended 30th June 2025 and as considered in the Statement. These interim financial results have been reviewed by other auditors whose reports have been furnished to us by the Parent's management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiary, is based solely on the reports of the other auditor and the procedures performed by us as stated in paragraph 3 above.

Our conclusion is not modified in respect of this matter.

For V.S. SOMANI & Co.,
Chartered Accountants
Firm Registration No. 117589W



C.A. Vidyadhar Somani
Proprietor
Membership No.102664
UDIN No. 25102664BMITHM3913

Place: Mumbai
Date: 7th August, 2025